INERT, here is another example where you have jumped to conclusions, or in other words, read more into the CDEx filing than was actually there IMO.
You wrote:
"...All we will ever know is that the first units were delivered, as noted in the PR, more than likely to BaXA,who have stated (at one time) that they had standing orders for 15 units."
Maybe you are correct and I missed something but what I remember is the CDEx filing stating that 15 out of 25 of the first Valimed production units (please note that term Moonie & Nasfan) had been set aside for sales or lease. Rottenapple already made this point weeks ago.
1. The filing does not explicitly state that 15 units have been sold/leased, they have only been "set aside" or reserved.
2. The most recent PR did not state how many units would be delivered to Baxa although I, along with most, I'm assuming it's the 15 units as stated in the filing.
Nevertheless, I fully expect that those first 15 units will be sold/leased immediately if there is any demand whatsoever.
Futher, I expect the 10 remaining units in CDEX's possession to be used to replace the production prototype/beta units (please note the term Moonie & Nasfan) currently in use at hospitals which will remain as CDEX "house accounts".
It is reasonable to assume that CDEX has established very close "partnerships" with some of the hospitals that have assisted CDEX with development of the Valimed library and they will continue this relationship into the future with the upgraded Valimed units.
For example, I would expect CDEx to continued to work closely with the Utah Cancer Center in developing signatures for Chemo drugs.
AI
